References
- Holmes F A, O'Shaughnessy J A, Vukelja S, Jones S E, Shogan J, Savin M, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727–731
- Smith T J, Khatcheressian J, Lyman G H, Ozer H, Armitage J O, Balducci L, et al. American Society of Clinical Oncology. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based, clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205
- Aapro M S, Cameron D A, Pettengell R, Bohlius J, Crawford L, Ellis M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433–2453
- Dale D C. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002; 62(Suppl 1)1–15
- Martin-Christin F. Granulocyte colony stimulating factors: How different are they? How to make a decision. Anti-cancer Drugs 2001; 12: 185–191
- George S, Yunus F, Case D, Yang B B, Hackett J, Shogan J E, et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with Non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1691–1696
- Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with Non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1503–1508
- Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tahbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–170
- Lubenau H, Bias P, Maly A, et al. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim NeupogenTM: single-blind, randomised, cross-over trial. BioDrugs, in press
- Lubenau H, Sveikata A, Gumbrevicius G, Macijauskiene J, Fokas V, Kazlauskas S, et al. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharm Ther, in press
- Eldar-Lissai A, Cosler L E, Culakova E, Lyman G H. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008; 11: 172–179
- Ozer H, Armitage J, Bennett C, Crawford J, Demetri G D, Pizzo P A, et al. American Society of Clinical Oncology. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558–3585